Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ICMT | O60725 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31387656 | 0.79 | ICMT (0.35) | SIRT1ICMTCA2P2RX7PLA2G2A | |
| SCHEMBL21535088 | 0.77 | GABRA1 (0.38) | — | |
| SCHEMBL2960718 | 0.76 | AR (0.43) | SIRT1 | |
| SCHEMBL13750888 | 0.75 | GAA (0.38) | HTTICMTCA2P2RX7 | |
| SCHEMBL28176483 | 0.74 | HTT (0.37) | SIRT1HTTICMTCA2 | |
| SCHEMBL18786842 | 0.73 | ERN1 (0.43) | CA2 | |
| SCHEMBL9926662 | 0.72 | ICMT (0.38) | SIRT1HTTICMTP2RX7 | |
| SCHEMBL23114101 | 0.72 | HPGD (0.36) | — | |
| SCHEMBL7120045 | 0.72 | HTT (0.38) | SIRT1HTTICMTCA2 | |
| SCHEMBL2952259 | 0.71 | P2RX7 (0.47) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772267-B2 | or other nuclear hormone receptors inhibitors; 4-(7-Hydroxy-1,3-dioxo-tetrahydropyrrolo[1,2-c]imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile; age-related diseases: sarcopenia, muscular atrophy, lipodistrophy, long-term critical illness, chronic fatigue syndrome, bone fracture repair | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7732480-B2 | Bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-08 | — | — | US | disclosed |
| US-7696241-B2 | Bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7405234-B2 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7388027-B2 | Bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080103188-A1 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080096954-A1 | Novel Bicyclic Compounds As Modulators of Androgen Receptor Function And Method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-24 | — | — | US | disclosed |
| EP-1722790-A4 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1729763-A4 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1506178-A4 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005089118-A2 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005086735-A2 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050197367-A1 | Novel bicyclic compounds as modulators of androgen receptor function and method | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-20050153968-A1 | Monocyclic N-aryl hydantoin modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005049580-A1 | MONOCYCLIC N-ARYL HYDANTOIN MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1506178-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | SIRT1 363/4885HTT 2194/4885ICMT 4771/4885 |
| US-20080096954-A1 | Novel Bicyclic Compounds As Modulators of Androgen Receptor Function And Method | AR, NR5A1, ESRRA | SIRT1 521/4885HTT 3719/4885ICMT 4876/4885 |
| US-20050197367-A1 | Novel bicyclic compounds as modulators of androgen receptor function and method | AR, NR5A1, ESRRA | SIRT1 447/4885HTT 3216/4885ICMT 4863/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | SIRT1 434/4885HTT 2277/4885ICMT 4796/4885 |
| US-20080108649-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | AR, ESRRA, SHBG | SIRT1 455/4885HTT 2061/4885ICMT 4561/4885 |
| US-20080103188-A1 | NOVEL BICYCLIC COMPOUNDS AS MODULATORS OF ANDROGEN RECEPTOR FUNCTION | AR, ESRRA, NR5A1 | SIRT1 377/4885HTT 2931/4885ICMT 4813/4885 |
| US-20050153968-A1 | Monocyclic N-aryl hydantoin modulators of androgen receptor function | AR, NR5A1, CYP19A1 | SIRT1 588/4885HTT 664/4885ICMT 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.